Stroke Hyperglycemia Insulin Network Effort (SHINE)Trial I-SPOT Ancillary Trial

> Nina Gentile, MD I-SPOT PI





I-SPOT Trial Summary

- Prelim data suggests markers of TF pathway activation are elevated in Type 2 DM stroke patients (T2DM) and are especially high after stroke.
- NIH-NINDS Ancillary Trial Proposal
 - Study the effect of glucose regulation on the TF pathway and to define the relationship between glucose levels, markers of activation of TF pathway, and clinical outcome after stroke.
 - Requires additional blood draw at enrollment and at 48 hours after the start of SHINE treatment



I-SPOT Trial Time Line

- Submitted summer 2011
- Reviewed Fall, 2011 Score 27
- Funding decision Council meeting February 2012
 Likely to be funded for Spring 2012 start date
- We will notify all sites as soon as decision known

